Foamix Pharmaceuticals Ltd.
CIK:0001606645|SEC Filings
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Income Statement [Abstract] | |||
| REVENUES (Note 13b) | $ 443 | $ 3,595 | $ 3,669 |
| COST OF REVENUES | 13 | ||
| GROSS PROFIT | 443 | 3,595 | 3,656 |
| OPERATING EXPENSES: | |||
| Research and development | 51,202 | 64,474 | 57,779 |
| Selling, general and administrative | 45,114 | 14,013 | 11,491 |
| TOTAL OPERATING EXPENSES | 96,316 | 78,487 | 69,270 |
| OPERATING LOSS | 95,873 | 74,892 | 65,614 |
| FINANCE INCOME (Note 13c) | (1,672) | (985) | (1,134) |
| FINANCE EXPENSES (Note 13c) | 1,153 | 44 | 71 |
| LOSS BEFORE INCOME TAX | 95,354 | 73,951 | 64,551 |
| INCOME TAX (Note 12) | (176) | 212 | 1,164 |
| NET LOSS FOR THE YEAR | $ 95,178 | $ 74,163 | $ 65,715 |
| LOSS PER SHARE BASIC AND DILUTED | $ 1.66 | $ 1.70 | $ 1.76 |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS | 57,292 | 43,660 | 37,376 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands |
Dec. 31, 2019 |
Dec. 31, 2018 |
|---|---|---|
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $ 43,759 | $ 27,868 |
| Restricted cash | 825 | 250 |
| Short term bank deposits | 12,102 | 24,047 |
| Investment in marketable securities (Note 4) | 16,246 | 46,669 |
| Restricted investment in marketable securities (Note 4) | 434 | 268 |
| Trade receivable | 135 | 1,066 |
| Other (Note 13a) | 1,557 | 999 |
| Inventory (Note 5) | 1,356 | |
| TOTAL CURRENT ASSETS | 76,414 | 101,167 |
| NON-CURRENT ASSETS: | ||
| Investment in marketable securities (Note 4) | 150 | |
| Restricted investment in marketable securities (Note 4) | 133 | |
| Property and equipment, net (Note 6) | 2,885 | 2,235 |
| Operating lease right of use assets (Note 7) | 1,694 | |
| Other | 166 | 46 |
| TOTAL NON-CURRENT ASSETS | 4,745 | 2,564 |
| TOTAL ASSETS | 81,159 | 103,731 |
| CURRENT LIABILITIES: | ||
| Trade payables | 19,352 | 6,327 |
| Accrued expenses | 3,381 | 351 |
| Employee related obligations | 5,231 | 3,498 |
| Operating lease liabilities (Note 7) | 1,092 | |
| Other | 270 | 292 |
| TOTAL CURRENT LIABILITIES | 29,326 | 10,468 |
| LONG-TERM LIABILITIES: | ||
| Liability for employee severance benefits (Note 8) | 424 | 367 |
| Operating lease liabilities (Note 7) | 653 | |
| Long-term debt (Note 10) | 32,725 | |
| Other liabilities | 456 | 714 |
| TOTAL LONG-TERM LIABILITIES | 34,258 | 1,081 |
| TOTAL LIABILITIES | 63,584 | 11,549 |
| COMMITMENTS AND CONTINGENCIES (Note 9) | ||
| SHAREHOLDERS' EQUITY: | ||
| Ordinary Shares, NIS 0.16 par value - authorized: 135,000,000 and 90,000,000 Ordinary Shares as of December 31, 2019 and December 31, 2018; issued and outstanding: 61,580,544 and 54,351,140 Ordinary Shares as of December 31, 2019 and December 31, 2018, respectively | 2,659 | 2,331 |
| Additional paid-in capital | 325,498 | 305,303 |
| Accumulated deficit | (310,587) | (215,409) |
| Accumulated other comprehensive income (loss) | 5 | (43) |
| TOTAL SHAREHOLDERS' EQUITY | 17,575 | 92,182 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ 81,159 | $ 103,731 |